Publicaciones (366) Publicaciones de JAVIER ANGULO CUESTA

2024

  1. Carlos Alférez and the conversion of «Actas de la AEU» into «Actas Urológicas Españolas»

    Actas Urologicas Espanolas

  2. Distinct spatial landscapes in clear-cell renal cell carcinoma as revealed by whole transcriptome analysis

    Immuno-Oncology and Technology, Vol. 21

  3. Multi-Institutional Outcomes of Dorsal Onlay Buccal Mucosal Graft Urethroplasty in Patients with Postprostatectomy, Postradiation Anastomotic Stenosis

    Journal of Urology, Vol. 211, Núm. 4, pp. 596-604

  4. Reply by Authors

    Journal of Urology

  5. The Expression of Alamandine Receptor MrgD in Clear Cell Renal Cell Carcinoma Is Associated with a Worse Prognosis and Unfavorable Response to Antiangiogenic Therapy

    International Journal of Molecular Sciences, Vol. 25, Núm. 3

2023

  1. Advances in Urological Cancer in 2022, from Basic Approaches to Clinical Management

    Cancers

  2. Claudin-3 Loss of Expression Is a Prognostic Marker in Castration-Resistant Prostate Cancer

    International Journal of Molecular Sciences, Vol. 24, Núm. 1

  3. Complications after Prostate Cancer Treatment: Pathophysiology and Repair of Post-Radiation Urethral Stricture Disease

    Journal of Clinical Medicine, Vol. 12, Núm. 12

  4. Effect of Neuro-Adaptive Electrostimulation Therapy versus Sham for Refractory Urge Urinary Incontinence Due to Overactive Bladder: A Randomized Single-Blinded Trial

    Journal of Clinical Medicine, Vol. 12, Núm. 3

  5. Factors Influencing Postoperative Overactive Bladder after Adjustable Trans-Obturator Male System Implantation for Male Stress Incontinence following Prostatectomy

    Journal of Clinical Medicine, Vol. 12, Núm. 24

  6. Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial

    European urology oncology, Vol. 6, Núm. 1, pp. 58-66

  7. Impact of the COVID-19 Pandemic on Cancer Diagnosis in Madrid (Spain) Based on the RTMAD Tumor Registry (2019–2021)

    Cancers, Vol. 15, Núm. 6

  8. Results of Adjustable Trans-Obturator Male System in Patients with Prostate Cancer Treated with Prostatectomy and Radiotherapy: A Multicenter Study

    Journal of Clinical Medicine, Vol. 12, Núm. 14

  9. Update on Adjustable Trans-Obturator Male System (ATOMS) for Male Incontinence after Prostate Cancer Surgery

    Current Oncology, Vol. 30, Núm. 4, pp. 4153-4165

2022

  1. A buccal mucosal graft subcoronal resurfacing technique to treat recurrent penile adhesions: the buccal belt

    BJU International, Vol. 129, Núm. 3, pp. 406-408

  2. ATOMS (Adjustable Trans-Obturator Male System) in Patients with Post-Prostatectomy Incontinence and Previously Treated Urethral Stricture or Bladder Neck Contracture

    Journal of Clinical Medicine, Vol. 11, Núm. 16

  3. ATOMS (Adjustable transobturator male system) is an effective and safe second‐line treatment option for recurrent urinary incontinence after implantation of an advance/advance XP fixed male sling. a multicenter cohort analysis

    Journal of Clinical Medicine, Vol. 11, Núm. 1

  4. Clear Cell Renal Cell Carcinomas with Aggressive Behavior Display Low Intratumor Heterogeneity at the Histological Level

    Current Urology Reports, Vol. 23, Núm. 6, pp. 93-97

  5. Compression or obstruction: Prospective analysis of the function of the Adjustable Transobturator Male System (ATOMS) based on pre- and postoperative urodynamic data

    Canadian Urological Association Journal, Vol. 16, Núm. 5, pp. E256-E260

  6. Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study

    World Journal of Urology, Vol. 40, Núm. 10, pp. 2459-2466